Rahul Thakur, Han Yu, Mariam Haji, Vaishali Deenadayalan, Vasanthan Kumarasamy, Ajinkya Buradkar, Jordan Scott, Grant Schofield, Dorothy Pan, Matthew Cortese, Francisco Hernandez-Ilizaliturri, Alex Niu. "Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola R+CHP) results in similar clinical outcomes than rituximab and dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R+DA-EPOCH) in patients with high-risk features diffuse large B-cell lymphoma (DLBCL): A single institution experience.." Blood, 2025. doi:10.1182/blood-2025-3685